Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
AstraZeneca
Mallinckrodt
Citi
UBS
Medtronic
Deloitte
Moodys
Accenture
Federal Trade Commission

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,849,726

« Back to Dashboard

Summary for Patent: 5,849,726
Title: Anhydrous alendronate monosodium salt formulations
Abstract:Disclosed is a method for treating and preventing bone loss in patients by administering a formulation of anhydrous alendronate sodium. Also described is a pharmaceutical dosage form of said anhydrous alendronate sodium, being anhydrous 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, monosodium salt, in a pharmaceutically acceptable excipient.
Inventor(s): Brenner; Gerald S. (Norristown, PA), Ostovic; Drazen (Lansdale, PA), Oberholtzer, Jr.; Earl R. (Hatfield, PA), Thies; J. Eric (Scotch Plains, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/973,386
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 5,849,726

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,849,726

PCT Information
PCT FiledJune 03, 1996PCT Application Number:PCT/US96/08284
PCT Publication Date:December 12, 1996PCT Publication Number: WO96/39149

International Patents Family Members for US Patent 5,849,726

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 5886096 ➤ Subscribe
Canada 2221417 ➤ Subscribe
Germany 69634357 ➤ Subscribe
Denmark 0833643 ➤ Subscribe
European Patent Office 0833643 ➤ Subscribe
Austria 289199 ➤ Subscribe
Spain 2236737 ➤ Subscribe
Japan H11506116 ➤ Subscribe
Japan 3344726 ➤ Subscribe
Portugal 833643 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Citi
Daiichi Sankyo
Mallinckrodt
Johnson and Johnson
Cantor Fitzgerald
Medtronic
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot